Molecular Biosystems' ultrasound agent enters trials in Japan:
This article was originally published in Clinica
Chugai Pharmaceuticals has begun clinical trials in Japan of Molecular Biosystems' (MBI) cardiac ultrasound imaging agent, Optison. MBI and Chugai entered a licensing agreement in April 1998 to develop and commercialise FS069 (the Japanese name for Optison) and another agent, Oralex. Japan is the world's second largest market for ultrasound imaging after the US.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.